Natco Pharma Limited

CLOSEOUT LETTER Natco Pharma Limited MARCS-CMS 672564 — September 25, 2025 More Warning Letters Warning Letters About Warning and Close-Out Letters Product: Drugs Recipient: Recipient Name Mr. Sandeep Kumar Recipient Title Vice President - Quality Natco Pharma Limited Pharma Division, Kothur Village Rangareddy 509228 Telangana India Issuing Office: Center for Drug Evaluation and Research (CDER) United States Secondary Issuing Offices United States Dear Mr. Kumar: The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter 320-24-32 dated August 8, 2024. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ Rafael Arroyo Compliance Officer Division of Drug Quality I Content current as of: 09/29/2025 Regulated Product(s) Drugs